Moderna’s Cancer Treatment: S&P 500 and VIX’s Unexpected Market Impact
724FinanceEge Kaan
Key Highlights
Moderna'nın yeni kanser tedavisi olan **mRNA-4157**, piyasada büyük bir heyecan yarattı. Tedavinin **90% oranında etkinliği** ve **önceki tedavilerden
Moderna’s new cancer treatment, mRNA-4157, has sparked significant market excitement. With an efficacy rate of 90% and fewer side effects than previous treatments, the company’s stock surged by 25%. This development triggered a VIX decline and a resurgence of the gamma squeeze, as investors began valuing the treatment’s potential. The S&P 500 options market also saw short-term pricing fluctuations.
The treatment’s success could boost Moderna’s earnings margins by 30%, while the VIX drop supported currency rates. This scenario increases the likelihood of the Federal Reserve delaying rate hikes. >
Related News & Analysis
View All →
Fed's Battle: Rate Hike Odds and Investor Expectations Shifted
Howard Marks' 52.4 Million Investment in MakeMyTrip Could Reshape India's Travel Market
OpenAI and Anthropic Clash Over Enterprise Data Privacy
UK's Water Crisis: Technological Solution Stalled by Legal Hurdles
Can Burnham’s Push to Rewire the ‘Treasury Brain’: Shifting Growth Policy to Manchester
Trump and Cohen's Miraculous Reconciliation: How Markets Are Reacting
Latest Market News
All News →
US Public Debt Surpasses $40 Trillion for First Time: How Markets Will React?
Chip Stock Rally Faces Short-Term Pressure — Analysts See Hope for Recovery
Bursa's Automotive Sector Announces 200-Job Hiring Drive
Tarsus' Historic Hotels: The New Engine of Faith Tourism
Üşümezsoy: Istanbul Earthquakes 'Not a Sign of Major Quake' - Not on Main Fault Line